AI assistant
Dr. Lal Pathlabs Limited — Earnings Release 2026
Apr 30, 2026
61783_rns_2026-04-30_469b3794-999d-44e6-8fba-db81022a241f.pdf
Earnings Release
Open in viewerOpens in your device viewer
Dr Lal PathLabs
April 30, 2026
National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051
BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001
Symbol: LALPATHLAB
Scrip Code: 539524
Sub: Press Release on Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2026
Dear Sir/ Madam,
Please find enclosed herewith the Press Release on the Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2026.
We request you to please take the same on record.
Thanking You,
Yours Faithfully,
For Dr. Lal PathLabs Limited
Vinay Gujral
Digitally signed
by Vinay Gujral
Date: 2026.04.30
16:02:42 +05'30'
Vinay Gujral
Company Secretary & Compliance Officer
Encl.: As above
Regd. Office: Dr. Lal PathLabs Ltd., Block E, Sector-18, Rohini, New Delhi - 110085, +91-11-30258600, Fax: +91-11-2788-2134
Corporate Office: Dr. Lal PathLabs Ltd., 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurugram - 122 001, Haryana +91-124-3016-500, Fax: +91-124-4234-468
Classification: Internal
E-mail: [email protected], Web: www.lalpathlabs.com, CIN No.: L74899DL1995PLC065388
Dr Lal PathLabs
For Immediate Release
April 30, 2026
Dr Lal PathLabs Limited records revenue of Rs 703 Cr with a growth of 16.6% in Q4 FY26
New Delhi, India, April 30, 2026 – Dr Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended March 31, 2026.
Consolidated Performance Highlights: Q4 FY26
- Revenue increased by 16.6% in Q4 FY26
- EBITDA for Q4 FY26 increased by 10.5% with a margin of 26.6%
- PAT for Q4 FY26 is Rs 132 Cr. with a margin for of 18.8%
- Final Dividend of 40% i.e. Rs. 4 per share.
- Cash and Cash equivalents as on 31st March, 2026 is Rs. 1,526 Cr.
Financial Overview (Consolidated) in Rs Cr
| Particulars | Q4 | Full Year | ||||
|---|---|---|---|---|---|---|
| FY26 | FY25 | Gr % | FY26 | FY25 | Gr % | |
| Revenue | 703 | 603 | 16.6% | 2763 | 2461 | 12.2% |
| Material consumed | 135 | 118 | 535 | 481 | ||
| Employee benefit Expenses | 129 | 109 | 533# | 456 | ||
| Fees to collection centres | 101 | 78 | 402 | 342 | ||
| Other Expenses | 151 | 129 | 540 | 487 | ||
| EBITDA | 187 | 169 | 10.5% | 752 | 696 | 8.2% |
| Margins | 26.6% | 28.1% | 27.2% | 28.3% | ||
| Other Income | 24 | 26 | 101 | 93 | ||
| Depreciation Cost | 45 | 36 | 162 | 142 | ||
| Finance Cost | 6 | 5 | 23 | 22 | ||
| PBT | 160 | 154 | 4.2% | 669 | 625 | 7.1% |
| Margins | 22.8% | 25.5% | 24.2% | 25.4% | ||
| Income Tax | 28 | (2) | 159 | 133 | ||
| PAT | 132 | 156 | -15.1% | 510 | 492 | 3.6% |
| Margins | 18.8% | 25.8% | 18.4% | 20.0% | ||
| EPS | 7.9 | 9.3 | -15.4% | 30.2 | 29.2 | 3.4% |
| Impact of new Labour Codes | - | - | 30 | - | ||
| One Time Tax Benefit SDPL Liquidation | - | (41) | - | (41) | ||
| Normalized EBITDA* | 187 | 169 | 10.5% | 783 | 696 | 12.5% |
| Margins | 26.6% | 28.1% | 28.3% | 28.3% | ||
| Normalized PAT* | 132 | 115 | 15.1% | 532 | 451 | 17.9% |
| Margins | 18.8% | 19.1% | 19.3% | 18.3% |
*Excluding one-time exceptional items
Including one-time impact of Labour Code
Dr Lal PathLabs Limited
12th Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com
Dr Lal PathLabs
About Dr Lal PathLabs Limited
Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.
As on March 31, 2026 the company has 312 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 7,727 Patient Service Centers (PSCs) and 13,935 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.
Contact Details
Ved Goel
Group Chief Financial Officer & CEO- International Business
Dr Lal PathLabs Limited
+91 124 3016500
[email protected]
Kritika Khatwani
Adfactors PR
+91 8604801332
[email protected]
For further information on Dr Lal PathLabs see www.lalpathlabs.com
Safe Harbour
This release contains statements that contain "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.
Dr Lal PathLabs Limited
12th Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com